Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
589 studies found for:    Open Studies | "Hormones"
Show Display Options
Rank Status Study
21 Recruiting Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
Conditions: Breast Neoplasms;   Breast Diseases;   Neoplasms;   Neoplasms by Site;   Fulvestrant;   Antineoplastic Agents;   Antineoplastic Agents, Hormonal;   Estrogen Receptor Antagonists;   Hormone Antagonists;   Hormones, Hormone Substitutes, and Hormone Antagonists;   Molecular Mechanisms of Pharmacological Action;   Pharmacologic Actions;   Therapeutic Use
Interventions: Drug: Ribociclib;   Drug: fulvestrant;   Drug: Ribociclib placebo
22 Recruiting Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Estrogen Receptor Positive Breast Cancer;   Progesterone Receptor Positive Tumor;   Metastatic Breast Cancer
Interventions: Drug: Palbociclib;   Drug: Tamoxifen
23 Recruiting Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (VRS-317)
Conditions: Pediatric Growth Hormone Deficiency;   Growth Disorders
Intervention: Drug: VRS-317
24 Unknown  Bone Structure in Patients With Adult Onset Growth Hormone Deficiency Assessed Using High Resolution Peripheral Quantitative Computed Tomography
Condition: Adult Onset Growth Hormone Deficiency
Intervention:
25 Recruiting Versartis Long-Term Safety Study of Somavaratan
Condition: Pediatric Growth Hormone Deficiency
Intervention: Drug: somavaratan
26 Recruiting Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD
Condition: Adult Growth Hormone Deficiency (AGHD)
Intervention: Drug: somavaratan
27 Unknown  Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency
Condition: Adults Growth Hormone Deficiency.
Interventions: Drug: Pegvisomant;   Drug: Regular insulin
28 Unknown  The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or GH Provocation Test
Conditions: Precocious Puberty;   Growth Hormone Tests
Intervention: Behavioral: Presence of medical clown during endocrine test
29 Recruiting Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Conditions: Breast Cancer Recurrent;   HER2/Neu-negative Carcinoma of Breast;   Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Everolimus;   Drug: Exemestane;   Other: Patient questionaires
30 Recruiting Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast;   Metastatic Breast Cancer
Intervention: Drug: Everolimus plus Exemestane
31 Recruiting Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
Conditions: Pituitary Neoplasms;   Prolactinoma;   ACTH-Secreting Pituitary Adenoma;   Gigantism;   Growth Hormone-Secreting Pituitary Adenoma
Intervention: Other: Educational Intervention
32 Not yet recruiting Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: Trametinib
33 Not yet recruiting Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Cabazitaxel;   Drug: Prednisone
34 Recruiting Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Cabazitaxel;   Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prednisone
35 Recruiting CYT107 After Vaccine Treatment (Provenge) in Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Biological: Glycosylated Recombinant Human Interleukin-7;   Other: Laboratory Biomarker Analysis
36 Not yet recruiting Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation;   Prostate Carcinoma Metastatic in the Bone;   Prostate Small Cell Carcinoma;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Cediranib;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
37 Recruiting Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Biological: Pembrolizumab;   Biological: pTVG-HP Plasmid DNA Vaccine
38 Recruiting Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Sirolimus
39 Recruiting Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy
40 Recruiting NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Prostate Carcinoma
Interventions: Procedure: Contrast-enhanced Magnetic Resonance Imaging;   Radiation: Fludeoxyglucose F-18;   Radiation: Fluorine F 18 Sodium Fluoride;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years